GlassScriptPhysician profile
Matthew P Gardner
NPI 1912123134
$196,136.57
in general payments reported to CMS, 2019-2025
17 companies · $48K in 2025
The $48K reported for 2025 was more than what 91% of Orthopaedic Trauma providers received nationally (typical 2025 total: $1,227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $19K · 2021: $4,318 · 2022: $31K · 2023: $26K · 2024: $27K · 2025: $48K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $34K · Royalty Or License: $33K · Consulting Fee: $13K · Travel and Lodging: $7,684 · Food and Beverage: $6,696 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,165 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $34,072.94 |
| Royalty Or License | $32,622.20 |
| Consulting Fee | $13,139.50 |
| Travel and Lodging | $7,684.39 |
| Food and Beverage | $6,696.26 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,164.53 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Curvafix, INC. | $55,750.99 | 2022-2025 | Curvafix Im Implant |
| Medical Device Business Services, INC. | $55,503.11 | 2019-2025 | Va-Lcp, Lcp, Vivigen Mis Delivery System |
| Globus Medical, INC. | $27,706.50 | 2024-2025 | Precice Intramedullary Limb Lengthening System, Precice® Intramedullary Limb Lengthening System |
| Nuvasive Specialized Orthopedics, INC. | $22,473.14 | 2019-2023 | Precice Intramedullary Limb Lengthening System |
| Synthes Gmbh | $22,051.36 | 2019-2025 | |
| Depuy Synthes Sales INC. | $7,724.32 | 2019-2025 | Tfn-Advance, Va-Lcp, Na |
| Orthofix Medical, INC. | $1,843.77 | 2025 | Truelok, Tl-Hex Truelok Hexapod System |
| Wardlow Enterprises | $1,200.00 | 2022 | |
| Zimmer Biomet Holdings, INC. | $1,003.08 | 2019-2025 | A.L.P.S., Affixus, Ncb |
| Stryker Corporation | $212.42 | 2019-2023 | T2 Alpha |
| Nuvasive, INC. | $196.61 | 2019 | |
| Illuminoss Medical, INC. | $161.96 | 2025 | |
| Smith+Nephew, INC. | $143.86 | 2022 | |
| Bone Support INC. | $67.17 | 2022 | |
| Endeavor Orthopaedics LLC | $49.36 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocomposites INC | $29.92 | 2024 | |
| Innovation Technologies INC | $19.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$14,850.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Gardner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.